A Phase I, Open Label, Single-centre Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 Administered Orally to Japanese Patients With Advanced Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 13 Jan 2017
At a glance
- Drugs AZD 8055 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 14 Jun 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 14 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.